In a nutshell
This study examined the risk of venous thromboembolism (VTE, a blood clot that forms in the veins of the legs, arms, or groin) in patients treated with lenalidomide (Revlimid). The study concluded that the risk of VTE was low with lenalidomide treatment.
Lenalidomide is an effective treatment already used in multiple myeloma and mantle cell lymphoma. Lenalidomide has been associated with an increased risk of VTE in multiple myeloma patients. Treatments to prevent VTE (prophylaxis) are often given to these patients.
Studies are examining the effectiveness of lenalidomide in patients with chronic lymphocytic leukemia (CLL) and other forms of non-Hodgkin’s lymphoma. It is not clear if it increases the risk of VTE in these patients.
Methods & findings
This study analyzed data from 60 previous studies, including 3043 patients treated with lenalidomide. Data from 46 other studies was also analyzed, including 2244 patients. Patients were diagnosed with CLL or non-Hodgkin’s lymphoma.
Among the 3043 patients, there were 98 VTE cases. The incidence rate in this group was 3.22%. Among the 2244 patients, there were 97 VTE cases. The incidence rate in this group was 4.32%.
There were no significant differences based on disease subtype.
The bottom line
This study concluded that the risk of VTE due to lenalidomide was low in patients with CLL or non-Hodgkin’s lymphoma.
The fine print
Not all studies included reported on possible cases of VTE. This could mean the rates of VTE in this analysis are over-estimated.
Discuss the risk of VTE, and whether prophylaxis is necessary, with your doctor.
Published By :
Leukemia & lymphoma
Mar 21, 2018